8 insiders reported 16 Form 4 transactions for Outlook Therapeutics, Inc. (OTLK) over the past 18 months (most recent 2026-08-14). Recent activity: Sukhtian Ghiath M. (Director) Buy 2.5M shares, GMS Ventures & Investments (Director) Buy 2.5M shares, Jahr Robert Charles (Chief Executive Officer) Buy 151,515 shares, KENYON LAWRENCE A (Chief Financial Officer) Buy 101,010 shares, Sukhtian Faisal Ghiath (Director) Buy 95,398 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Sukhtian Ghiath M. | Director | Buy | 2.5M | $2.5M |
| 2026-08-14 | GMS Ventures & Investments | Director | Buy | 2.5M | $2.5M |
| 2026-08-14 | Jahr Robert Charles | Chief Executive Officer | Buy | 151,515 | $0 |
| 2026-08-14 | KENYON LAWRENCE A | Chief Financial Officer | Buy | 101,010 | $0 |
| 2026-07-29 | Sukhtian Faisal Ghiath | Director | Buy | 95,398 | $99,996 |
| 2026-06-03 | Haddadin Yezan Munther | Director | Buy | 29,000 | $24,145 |
| 2026-06-01 | Sukhtian Ghiath M. | Director | Buy | 8.5M | $5.0M |
| 2026-06-01 | GMS Ventures & Investments | Director | Buy | 8.5M | $5.0M |
| 2026-05-27 | HILZINGER KURT J | Director | Buy | 400,000 | $176,520 |
| 2026-05-27 | THURMAN RANDY H | Director | Buy | 5,000 | $2,145 |
| 2026-05-27 | Sukhtian Faisal Ghiath | Director | Buy | 122,174 | $50,006 |
| 2026-05-27 | Haddadin Yezan Munther | Director | Buy | 34,000 | $14,960 |
| 2025-05-28 | Sukhtian Ghiath M. | Director | Buy | 4.3M | $6.0M |
| 2025-05-28 | GMS Ventures & Investments | Director | Buy | 4.3M | $6.0M |
| 2025-03-12 | Sukhtian Ghiath M. | Director | Buy | 3.5M | $8.7M |
| 2025-03-12 | GMS Ventures & Investments | Director | Buy | 3.5M | $8.7M |
Source: SEC Form 4 filings · as of 2026-08-14